Analgesia News and Research RSS Feed - Analgesia News and Research

APS announces recipients of prestigious achievement awards during annual scientific meeting

APS announces recipients of prestigious achievement awards during annual scientific meeting

The American Pain Society (APS), www.americanpainsociety.org, today announced the recipients of its prestigious achievement awards during the organization's annual scientific meeting. [More]
New compound offers longer lasting painkilling effects

New compound offers longer lasting painkilling effects

Medications have long been used to treat pain caused by injury or chronic conditions. Unfortunately, most are short-term fixes or cause side effects that limit their use. Researchers at the University of Missouri have discovered a new compound that offers longer lasting painkilling effects, and shows promise as an alternative to current anesthetics. [More]
Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Positive CHMP opinion recommends RELISTOR for treatment of opioid-induced constipation

Valeant Pharmaceuticals International, Inc. and Progenics Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for RELISTOR (methylnaltrexone bromide) Subcutaneous Injection for the treatment of opioid-induced constipation (OIC) when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. [More]
Acacia Pharma begins APD421 Phase 3 study in combination with standard anti-emetics for PONV

Acacia Pharma begins APD421 Phase 3 study in combination with standard anti-emetics for PONV

Acacia Pharma Ltd, the supportive care company developing products for US and international markets, announces the initiation of a Phase 3 study investigating APD421 in combination with standard anti-emetics, in the prevention of post-operative nausea & vomiting (PONV) in high-risk patients. PONV remains a clinically significant problem in patients undergoing surgery, despite the availability of a range of anti-emetic medications. [More]
New website provides information to help lower anxiety before outpatient surgery in children

New website provides information to help lower anxiety before outpatient surgery in children

A newly developed website provides parents and children with individualized information and support -- based on factors like coping style and levels of worry and fear -- to help lower anxiety before outpatient surgery in children, according to a pair of articles in the April issue of Anesthesia & Analgesia. [More]
MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

MOVANTIK (naloxegol) now available in U.S. for treatment of OIC in adult patients with non-cancer pain

Nektar Therapeutics reported that partner AstraZeneca announced today that MOVANTIK (naloxegol) has launched in the United States. On September 16, 2014, the US Food and Drug Administration (FDA) approved MOVANTIK as the first once-daily oral peripherally-acting mu-opioid receptor antagonist (PAMORA) medication for the treatment of opioid-induced constipation (OIC) in adult patients with chronic, non-cancer pain. [More]
Data demonstrates benefits associated with use of EXPAREL in hip, knee replacement patients

Data demonstrates benefits associated with use of EXPAREL in hip, knee replacement patients

Pacira Pharmaceuticals, Inc. today announced data demonstrating the benefits associated with the use of EXPAREL (bupivacaine liposome injectable suspension) in a study of over 2,200 hip and knee replacement patients. [More]
Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet announces plans to commercialize SPRIX Nasal Spray and OXAYDO tablets

Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative pain treatments, today announced its plans for the commercialization of SPRIX (ketorolac tromethamine) Nasal Spray and OXAYDO (oxycodone HCI, USP) tablets for oral use only –CII. [More]
Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo signs co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol)

Daiichi Sankyo, Inc. today announced a co-commercialization agreement with AstraZeneca for MOVANTIK (naloxegol) in the US, in line with the Daiichi Sankyo strategy to expand its US portfolio through strategic alliances, in addition to internal R&D and acquisitions. [More]
AcelRx announces dosing of first patient in pivotal ARX-04 Phase 3 study for treatment of acute pain

AcelRx announces dosing of first patient in pivotal ARX-04 Phase 3 study for treatment of acute pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today reported dosing of the first patient in the pivotal Phase 3 study of ARX-04. [More]
Egalet announces net revenues of $1.9 million for 2014

Egalet announces net revenues of $1.9 million for 2014

Egalet Corporation today reported financial results for the year ended December 31, 2014. [More]
Study suggests distinct role of brain regions in dental pain relief

Study suggests distinct role of brain regions in dental pain relief

Today at the 93rd General Session and Exhibition of the International Association for Dental Research, researcher Michael L. Meier, Center for Dental Medicine, University of Zürich, Switzerland, will present a study titled "Distinct Brain Mechanisms Related to Dental Pain Relief." [More]
Kaleo, CHMI partner to reduce prescription drug-related deaths

Kaleo, CHMI partner to reduce prescription drug-related deaths

Kaleo, a privately-held pharmaceutical company, today announced a national strategic partnership with the Clinton Health Matters Initiative, an initiative of the Clinton Foundation, that will help support its goal of cutting prescription drug-related deaths in half, saving approximately 10,000 lives over five years. [More]
Secrets of success for pioneering research revealed

Secrets of success for pioneering research revealed

The British Pharmacological Society has announced the secrets of success for pioneering research along with the outcome of its annual 'Putting UK Pharmacology on the Map' vote. The vote selects sites of special scientific interest linked to achievements in pharmacology based on a ballot of MPs, peers and senior members of the scientific community. [More]
AcelRx Pharmaceuticals' Zalviso device gets CE Mark approval

AcelRx Pharmaceuticals' Zalviso device gets CE Mark approval

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has received CE Mark approval (Conformite Europeenne) for the Zalviso device. [More]
New data shows EXPAREL provides effective pain control following total knee arthroplasty

New data shows EXPAREL provides effective pain control following total knee arthroplasty

Pacira Pharmaceuticals, Inc. today announced results of an independent, physician-initiated study designed to evaluate the difference in postsurgical pain and opioid consumption between patients who received EXPAREL versus a multi-drug analgesic cocktail for pain management following total knee arthroplasty (TKA). [More]
Hospira launches Paricalcitol Injection

Hospira launches Paricalcitol Injection

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, today announced the launch of Paricalcitol Injection, a generic version of AbbVie's Zemplar. Hospira obtained U.S. Food and Drug Administration approval of paricalcitol on Oct. 21 and launched the product Nov. 1. [More]
Cogent OA teams up with Medpharm Publications to co-publish society-affiliated journals

Cogent OA teams up with Medpharm Publications to co-publish society-affiliated journals

Cogent OA is delighted to announce a partnership with Medpharm Publications of South Africa to co-publish several of its society-affiliated journals, providing leading online functionality and marketing services to further increase visibility and global reach. [More]

Union Hospital expands use of capnography to strengthen patient safety

Union Hospital recently strengthened patient safety measures by expanding its use of capnography to monitor patients capnography during patient-controlled analgesia (PCA) to regulate their pain after surgery. [More]
Henrik Kehlet recognized with ASA's 2014 Excellence in Research Award

Henrik Kehlet recognized with ASA's 2014 Excellence in Research Award

The American Society of Anesthesiologists today presented Henrik Kehlet, M.D., Ph.D., with its 2014 Excellence in Research Award in recognition of his outstanding contributions to research which have had an important impact on anesthesiology as a medical specialty. [More]
Advertisement
Advertisement